Autres langues Trevi Therapeutics, Inc.

Actions

TRVI

US89532M1018

Temps réel estimé Cboe BZX Autres places de cotation 20:04:50 30/05/2024			Varia. 5j.	Varia. 1 janv.
2,61 ^USD	+2,76 %		+3,54 %	+96,27 %

07/05	Transcript : Trevi Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024
07/05	Trevi Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Trevi Therapeutics to Participate in Upcoming Conferences	09/05
Trevi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates	07/05
Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024	01/05
Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference	10/04
Trevi Therapeutics to Participate in Upcoming April Events	04/04
Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team	02/04
Trevi Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
Trevi Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	20/03
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates	20/03
Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024	13/03
Trevi Therapeutics to Participate in Upcoming March Events	28/02
Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference	06/02
Trevi Therapeutics Provides Business Updates	04/01
Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio for Chronic Cough in Idiopathic Pulmonary Fibrosis	06/12
Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)	05/12
Trevi Therapeutics, Inc. Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio? for Chronic Cough in Idiopathic Pulmonary Fibrosis	05/12
Trevi Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Trevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update	09/11
Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio for Refractory Chronic Cough	03/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Trevi Therapeutics, Inc.

Actions

TRVI

US89532M1018

Autres langues

Filtres